Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie
| Autor: | Marie Wislez, Cécile Hamard, Martine Antoine, N. Rozensztajn, Armelle Lavolé, Jacques Cadranel, Anne-Marie Ruppert |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Crizotinib Ceritinib business.industry medicine.drug_class medicine.disease_cause respiratory tract diseases Pathology and Forensic Medicine ALK inhibitor 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Gefitinib 030220 oncology & carcinogenesis medicine ROS1 Cancer research KRAS Rociletinib business neoplasms medicine.drug EGFR inhibitors |
| Zdroj: | Annales de Pathologie. 36:63-72 |
| ISSN: | 0242-6498 |
| DOI: | 10.1016/j.annpat.2015.11.002 |
| Popis: | Recently, developments of therapies that target abnormally activated signaling pathways are increasing for patients with non-small cell lung cancer. EGFR mutations are found in about 10% of lung cancers, especially in adenocarcinoma, women and non-smokers. Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. Effectiveness of EGFR inhibitors is higher than conventional chemotherapy. Third generation EGFR inhibitors (rociletinib, AZD9291) are effective for patients who develop a resistance mutation such as T790M resistance mutation; they obtained temporary authorization for use in France in 2015. The EML4-ALK translocation is found in about 5% of NSCLC and more particularly in adenocarcinoma of young non-smoking patients. Crizotinib is a new therapeutic standard in ALK translocated NSCLC in second line. Ceritinib is a 2nd generation ALK inhibitor which received a European marketing authorization for up to treatment of ALK translocated NSCLC after progression with crizotinib. INCA supports ACSe program evaluating the efficacy of crizotinib in NSCLC amplified for MET or translocated for ROS1 and ACSe program evaluating the efficacy of vemurafenib in tumors non melanoma mutated V600E BRAF. The role of other biomarkers such as KRAS, BRAF, HER2 and PI3KCA mutations remains to be defined in NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|